WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 17.46 HKD 0.46% Market Closed
Market Cap: 72.5B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note

WuXi Biologics (Cayman) Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi Biologics (Cayman) Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
WuXi Biologics (Cayman) Inc
HKEX:2269
Operating Income
ÂĄ3.9B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Operating Income
ÂĄ10.6B
CAGR 3-Years
33%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Operating Income
ÂĄ1.6B
CAGR 3-Years
5%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Operating Income
ÂĄ1.4B
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
27%
M
MGI Tech Co Ltd
SSE:688114
Operating Income
-ÂĄ742.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Operating Income
ÂĄ410.8m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi Biologics (Cayman) Inc
Glance View

Market Cap
72.5B HKD
Industry
Life Sciences Tools & Services

WuXi Biologics (Cayman) Inc. emerged from the bustling arena of global pharmaceuticals as a beacon of innovation and flexibility in the biologics manufacturing space. Founded in 2010, this Chinese firm quickly established itself as a key player by offering a comprehensive suite of services that span the entire biologics development process. The company's strategy revolves around its "Follow-the-Molecule" business model, characterized by a symbiotic partnership with clients from the early stages of drug discovery through clinical development and all the way to commercial manufacturing. This approach ensures not only seamless integration across different development stages but also cultivates long-term relationships with clients, including startups and large pharmaceutical giants. Utilizing state-of-the-art technologies and an expansive network of manufacturing facilities around the globe, WuXi Biologics has positioned itself as an indispensable partner for firms looking to bring new biologics to market swiftly and efficiently. The revenue model of WuXi Biologics hinges on its ability to offer flexible, customer-centric solutions in a highly demanding industry. Unlike traditional pharmaceutical companies that solely profit from drug sales, WuXi Biologics earns money by leveraging its Contract Development and Manufacturing Organization (CDMO) platform to provide end-to-end services. This includes process development, clinical trials, regulatory submissions, and commercial production. The company capitalizes on strategic partnerships and its burgeoning pipeline of projects, earning fees at each stage of the drug development cycle. By ensuring proprietary access to its advanced technologies and broad capabilities, WuXi Biologics not only supports its clients' needs but also fortifies its revenue streams via milestone payments, service fees, and long-term manufacturing contracts. Such a business model not only diversifies its income but also mitigates risks associated with drug development uncertainty, allowing the company to thrive in the competitive global healthcare market.

Intrinsic Value
32.48 HKD
Undervaluation 46%
Intrinsic Value
Price

See Also

What is WuXi Biologics (Cayman) Inc's Operating Income?
Operating Income
3.9B CNY

Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Operating Income amounts to 3.9B CNY.

What is WuXi Biologics (Cayman) Inc's Operating Income growth rate?
Operating Income CAGR 5Y
34%

Over the last year, the Operating Income growth was -12%. The average annual Operating Income growth rates for WuXi Biologics (Cayman) Inc have been 10% over the past three years , 34% over the past five years .

Back to Top